Korean Drug Co. Ltd Cash Flow Conversion Efficiency

Latest as of June 2026: 0.024x

Korean Drug Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, Korean Drug Co. Ltd (014570) has a cash flow conversion efficiency ratio of 0.024x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.90 Billion ≈ $1.29 Million USD) by net assets (₩78.82 Billion ≈ $53.41 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Korean Drug Co. Ltd (2014–2025)

Cash flow conversion efficiency of Korean Drug Co. Ltd from 2014 to 2025. This chart illustrates how Korean Drug Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 014570 share price today for real-time trading data and today's change.

Korean Drug Co. Ltd Cash Flow Conversion Ratio Explained

Korean Drug Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Korean Drug Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Korean Drug Co. Ltd ranked by their cash flow conversion efficiency. Also see Korean Drug Co. Ltd (014570) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
9F Inc NASDAQ:JFU	0.038x
Diagnos Laboratorium Utama PT Tbk JK:DGNS	0.008x
Alpha Exploration Ltd V:ALEX	-0.010x
Personal Assets Trust plc LSE:PNL	-0.004x
Sidiz Inc KO:134790	0.077x
Allied Industrial Ltd TWO:4702	-0.006x
MegaMD Co. Ltd KQ:133750	-0.005x
Rex Industry Bhd KLSE:9946	-0.051x

Annual Cash Flow Conversion Efficiency for Korean Drug Co. Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Korean Drug Co. Ltd from 2014 to 2025. Review Korean Drug Co. Ltd (014570) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩83.07 Billion ≈ $56.30 Million	₩13.11 Billion ≈ $8.88 Million	0.158x	+153.18%
2024-12-31	₩78.11 Billion ≈ $52.93 Million	₩4.87 Billion ≈ $3.30 Million	0.062x	+340.45%
2023-12-31	₩77.09 Billion ≈ $52.24 Million	₩-2.00 Billion ≈ $-1.35 Million	-0.026x	-137.14%
2022-12-31	₩84.71 Billion ≈ $57.41 Million	₩5.91 Billion ≈ $4.01 Million	0.070x	-39.22%
2021-12-31	₩76.69 Billion ≈ $51.97 Million	₩8.81 Billion ≈ $5.97 Million	0.115x	-34.00%
2020-12-31	₩70.87 Billion ≈ $48.03 Million	₩12.33 Billion ≈ $8.36 Million	0.174x	+82.29%
2019-12-31	₩65.05 Billion ≈ $44.08 Million	₩6.21 Billion ≈ $4.21 Million	0.095x	+3.56%
2018-12-31	₩62.80 Billion ≈ $42.56 Million	₩5.79 Billion ≈ $3.92 Million	0.092x	+1074.16%
2017-12-31	₩56.97 Billion ≈ $38.61 Million	₩447.20 Million ≈ $303.06K	0.008x	-89.37%
2016-12-31	₩53.66 Billion ≈ $36.37 Million	₩3.96 Billion ≈ $2.69 Million	0.074x	-40.18%
2015-12-31	₩49.68 Billion ≈ $33.67 Million	₩6.13 Billion ≈ $4.16 Million	0.123x	+34.95%
2014-12-31	₩48.79 Billion ≈ $33.06 Million	₩4.46 Billion ≈ $3.02 Million	0.091x	--

About Korean Drug Co. Ltd

KQ:014570 Korea Drug Manufacturers - General

Market Cap

$20.65 Million

₩30.48 Billion KRW

Market Cap Rank

#24843 Global

#1806 in Korea

Share Price

₩2815.00

Change (1 day)

-0.35%

52-Week Range

₩2810.00 - ₩4475.00

All Time High

₩13030.58